Monoclonal antibodies in pediatric allergy
JPNIM Vol. 4 N. 2 - Cover


monoclonal antibodies (mAbs)
severe asthma
chronic spontaneous urticaria
anti-IgE mAbs

How to Cite

Licari, A., Castagnoli, R., Marseglia, A., Bottino, C., Corana, G., Guerini, P., Zaroli, A., Caimmi, S., & Marseglia, G. L. (2015). Monoclonal antibodies in pediatric allergy. Journal of Pediatric and Neonatal Individualized Medicine (JPNIM), 4(2), e040232.


Production of monoclonal antibodies (mAbs) involving human-mouse hybrid cells was first described in 1970s, but these biologics are now used for a variety of diseases including cancers, autoimmune disorders and allergic diseases. The aim of this article is to review current and future applications of mAbs, in particular focusing on anti-IgE therapy, in the field of pediatric allergy.


Proceedings of the 11th International Workshop on Neonatology and Satellite Meetings · Cagliari (Italy) · October 26th-31st, 2015 · From the womb to the adult
Guest Editors: Vassilios Fanos (Cagliari, Italy), Michele Mussap (Genoa, Italy), Antonio Del Vecchio (Bari, Italy), Bo Sun (Shanghai, China), Dorret I. Boomsma (Amsterdam, the Netherlands), Gavino Faa (Cagliari, Italy), Antonio Giordano (Philadelphia, USA)